Chimeric antigen receptor (CAR) T cell therapy has the potential to fundamentally shift the treatment of autoimmune disease. During his presentation at EULAR 2024, Georg Schett, MD, provided an overview of this treatment process and described the promising findings of the latest research.
Targeting Disease-Causing Cells: RheumMadness 2022 Chimeric Antigen Receptor T Cells Scouting Report
CD19 chimeric antigen receptor T (CAR-T) cell therapies may have the potential to treat rheumatic diseases in which current therapeutic options are limited, such as lupus, interstitial lung disease and systemic sclerosis.